Latest News and Press Releases

MONTRÉAL, 24 juill. 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », « la Société », « nous » ou « notre ») (TSXV : LOVE) (OTCQB : LOVFF) (FRA : 8CB0), un producteur verticalement...

Cannara secures 5 vape listings in Québec, including live rosin vapes, marking a major milestone as the province opens its vape cartridge market.

SALT LAKE CITY, UT, ROCHESTER, NY, Jan. 16, 2024 (GLOBE NEWSWIRE) -- CallTower, a global leader in delivering enterprise-class cloud communication solutions, was recognized by Frost & Sullivan...

SOMERSET, N.J., Oct. 10, 2023 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDP, CCLDO), a leader in healthcare technology solutions for medical practices and health systems nationwide, today...

NEWPORT BEACH, Calif. and LEHI, UT, June 20, 2023 (GLOBE NEWSWIRE) -- Verb Technology Company, Inc. (Nasdaq: VERB) (“VERB” or the “Company”), the leader in interactive video-based sales-enablement...

NEWPORT BEACH, Calif. and LEHI, Utah, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Verb Technology Company, Inc. (NASDAQ: VERB) ("VERB" or the "Company"), the leader in interactive video-based sales-enablement...

- Hyloris vise à obtenir l’approbation réglementaire en Europe, avec des extensions hors Europe possibles - Environ 5% des patients hospitalisés est diagnostiqué chaque année en hypophosphatémie1,...

Hyloris targets regulatory approval in Europe, with possible further extensionsAbout 5% of hospitalized patients is diagnosed with hypophosphatemia, with part of them needing direct treatment during...

Hyloris Pharmaceuticals Elargit son Portefeuille de Produits avec un Produit Candidat Intranasal Propriétaire d'un Agoniste TRPV11 (HY-083) pour la Rhinite Idiopathique - Hyloris cible une...

Hyloris Pharmaceuticals Broadens Pipeline with a Proprietary Intranasal Product Candidate of a TRPV11 agonist (HY-083) for Idiopathic Rhinitis Hyloris targets a condition that affects up to 7% of...